ArticleJournal of the American College of Cardiology2022
Association of Thromboxane Generation With Survival in Aspirin Users and Nonusers.
Article in Journal of the American College of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.British journal of cancer · 2023Trial
- EnhancedSkin health and disease · 2026Article
- Modifiable Correlates With Systemic Thromboxane Generation and Association With Cardiovascular Outcomes: Results From the Framingham Heart Study.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Research progress on beta-blockers in the treatment of sepsis-induced cardiomyopathy: A mini review.SAGE open medicine · 2026Review
- The crucial role of thromboxane AFrontiers in pharmacology · 2026Review
- Platelet activation, aspirin, and cancer: From basic science to clinical trials.Pharmacological reviews · 2026Review
- Exploiting the 2-(1,3,4,9-tetrahydropyrano[3,4-Journal of medicinal chemistry · 2025Article
- Hunting for a coronary artery disease diagnosis in asymptomatic patients with diabetes mellitus: if, how and when.Cardiovascular diabetology · 2025Review
- Aspirin loading in coronary artery disease patients already taking aspirin: A systematic review.Journal of cardiovascular and thoracic research · 2025Review
- Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure.Journal of the American College of Cardiology · 2025Article
- Oral P2YEuropean cardiology · 2025Review
- Factors associated with aspirin resistance in diabetic patients: A metabolic and inflammatory profile analysis.PloS one · 2025Article
- U-TXM: a novel biomarker for early detection of diabetic kidney disease.Frontiers in endocrinology · 2025Article
- Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.European heart journal · 2024Article
- Adjustment for Renal Function Improves the Prognostic Performance of Urinary Thromboxane Metabolites.Clinical chemistry · 2024Article
- Effect of very long-term storage and multiple freeze and thaw cycles on 11-dehydro-thromboxane-BScientific reports · 2024Article
- The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin EInternational journal of cancer · 2024Article
- Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients.Cancers · 2023Article
- Precision antiplatelet therapy.Research and practice in thrombosis and haemostasis · 2023Article
- Cardiovascular health: an important component of cancer survivorship.BMJ oncology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPersistent systemic thromboxane generation, predominantly from nonplatelet sources, in aspirin (ASA) users with cardiovascular disease (CVD) is a mortality risk factor.
objectivesThis study sought to determine the mortality risk associated with systemic thromboxane generation in an unselected population irrespective of ASA use.
methodsStable thromboxane B
resultsIn 1,363 (44.8%) participants taking ASA at the index examination, median TXB
conclusionsSystemic thromboxane generation is an independent risk factor for all-cause and cardiovascular mortality irrespective of ASA use, and its measurement may be useful for therapy modification, particularly in those without CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.